Risk factors
PepGen (PEPG) risk factors
Item 1A of every PepGen Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors112 risks11 new11 dropped30 reworded
PepGen faces heightened cash concerns, requiring funding past the 2026 FREEDOM2 data readouts, while narrowing focus to PGN-EDODM1.
Filed Mar 04, 2026 - FY2024 10-K risk factors112 risks
PepGen has a history of operating losses with $271.5 million in accumulated deficits and no approved products. The company relies entirely on third parties for drug manufacturing and clinical trial execution. Drug candidates target rare genetic neuromuscular diseases via an unproven EDO platform.
Filed Feb 24, 2025